Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

This is a proof-of-concept, Open label, randomized, multicentric, superiority phase-2 study.

Trial Details

NCT ID
NCT05821556
Phase
PHASE2
Sponsor
National Cancer Institute, Naples
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Valproic acid
  • Simvastatin 20mg
  • Gemcitabine 1000 mg
  • Nab paclitaxel
  • Cisplatin
  • Capecitabine
Locations (sample)
  • Naples, Italy, Italy|40.85216,14.26811
  • Milan, Milano, Italy|42.78235,12.59836
  • Roma, Roma, Italy|44.99364,11.10642
  • Verona, Verona, Italy|45.43854,10.9938
  • Madrid, Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Written informed consent to study procedures and to correlative studies.
  • Histologically or cytologically proven metastatic PDAC.
  • No prior treatments (chemotherapy, radiation or surgery) for PDAC
  • Either sex aged ≥ 18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →